LKLaurent Kaiser

Laurent Kaiser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurent Kaiser has a total of 625 co-authors. Here are the top co-authors by number of shared publications:

  • Isabella Eckerle

    Centre for Emerging Viral Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva Switzerland

    20 shared publications
  • Sabine Yerly

    Virology Laboratory, Hôpitaux Universitaires de Genève, P.O. Box 1205, 1211 Geneva, Switzerland

    13 shared publications
  • Samuel Cordey

    Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals & Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland

    13 shared publications
  • Caroline Tapparel

    Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland

    12 shared publications
  • Silvia Stringhini

    Affiliations Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland, School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada, Faculty of Medicine, University of Geneva, Geneva, Switzerland, Edwin S.H. Leong Centre for Healthy Aging, Faculty of Medicine, University of British Columbia, Vancouver, Canada

    12 shared publications
  • Benjamin Meyer

    University of Geneva

    10 shared publications

Latest Publications

  • Open Access

    Protocol for the National Data Stream IICU: a multicentre Swiss platform integrating multimodal clinical and pathogen data for personalized prediction of infection-related outcomes in intensive care

    by Catherine R. Jutzeler, Karsten Borgwardt, Nora Toussaint, Magdalena Lukamowicz-Rajska, Manuel Battegay, Filippo Boroli, Silvio D. Brugger, Andrea Büchler, Thierry Calandra, Jean-Daniel Chiche, et al.

  • Open Access

    Swiss community-based surveillance of respiratory virus co-occurrence in 2022–2024

    by Francisco Javier Pérez-Rodríguez, Ana Rita Goncalves Cabecinhas, Patricia Suter-Boquete, Tania Spedaliero, Nicolas Hulo, Laurent Kaiser, Isabella Eckerle, Manel Essaidi-Laziosi

    Viral respiratory infections (VRIs) are a persistent global health concern, driven by the year-round circulation of diverse viruses. During the coronavirus disease 2019 (COVID-19) pandemic, the prevalence of most respiratory viruses declined sharply following nonpharmaceutical interventions. Their subsequent resurgence and co-circulation with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) created a novel and unpredictable VRI landscape. We investigated the respiratory virus dynamics and co-occurrence patterns in symptomatic outpatients in Switzerland, using nasopharyngeal specimens collected between August 2022 and July 2024 by the National Reference Center for Influenza. In total, 5,369 specimens were tested by PCR or RT-PCR for 16 respiratory viruses. Co-detections were identified in 9% of positive samples and occurred year-round. The majority involved two viruses (92%), although triple and quadruple detections were also observed. Statistical analysis showed that multiple detections were significantly more common in children. Their incidence was higher not only with the most prevalent ones, rhinoviruses (RVs) and SARS-CoV-2, but also with bocaviruses (hBoV) and adenoviruses (ADVs). A statistically significant decrease in viral load was observed when a second virus was co-detected with SARS-CoV-2 or respiratory syncytial virus (RSV), but not with influenza viruses. This effect was most pronounced in early- and middle-aged adults. Through the systematic investigation of viral co-occurrence, this study emphasizes the importance of community-based surveillance. Beyond monitoring respiratory disease burden, such surveillance provides a foundation for generating hypotheses to better understand viral interactions and the virus-host interplay during infection. IMPORTANCE: Viral respiratory infections (VRIs) are a major public health challenge due to their constant circulation and significant impact on vulnerable populations. The coronavirus disease 2019 (COVID-19) pandemic profoundly altered the dynamics of respiratory viruses, leading first to a sharp decline in their prevalence, followed by an unpredictable resurgence in co-circulation with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In this context, understanding viral interactions and their co-detection in the community has become essential. This project provides novel insights into the frequency and characteristics of viral co-infections in a real-world outpatient setting. It highlights age-related differences and demonstrates statistically significant effects on viral load, particularly for SARS-CoV-2 and respiratory syncytial virus (RSV). These findings underscore the importance of community-based surveillance, not only to monitor the overall burden of respiratory diseases but also to generate new hypotheses on virus-host interactions. Ultimately, this knowledge can guide the development of more effective prevention and management strategies.

  • Open Access

    Comparative analytical sensitivity evaluation of five mpox point-of-care assays for mpox clades Ia, Ib, IIa and IIb

    by Kenneth Adea, Camille Escadafal, Devy M. Emperador, Emmanuel Agogo, Megan O’driscoll, Placide Mbala-Kingebeni, Laurent Kaiser, Meriem Bekliz, Isabella Eckerle

    Backgrounds: Following an increase in mpox clade Ib cases in several African countries, the World Health Organization recognized mpox as a public health emergency of international concern, highlighting the need for reliable and accessible diagnostic tools. As several mpox clades are co-circulating in endemic countries, the analytical sensitivity of diagnostic assays should be evaluated for all of them in a comparative manner. Methods: This study evaluated the analytical sensitivity of three rapid tests (Flowflex Monkeypox virus rapid test from ACON Biotech, Monkeypox antigen rapid test from Assure Tech, and Standard Q Monkeypox Ag Test from SD Biosensor) and two point-of care molecular tests (SD Biosensor’s M10 and Cepheid’s Xpert MPOX assays) using serial dilutions of viral stocks from the four clades of Monkeypox virus (MPXV): Ia, Ib, IIa, and IIb. Findings: Upon our analytical comparative benchmarking, the three rapid tests demonstrated comparable analytical sensitivity for all four clades, with a limit of detection of approximately 1,000,000 DNA copies/mL or 1,000 FFU/mL. The two molecular tests demonstrated also comparable analytical sensitivity to an in-house PCR assay for all four clades, detecting concentrations down to 10-100 DNA copies per mL, corresponding to a non-detectable titer of infectious particles. The Xpert assay detected the Clade Ib strain only through its orthopoxvirus target and not its MPXV target, and none of the assays could distinguish between MPXV clades. Interpretation: No differences in sensitivity was observed across MPXV clades neither for Ag-RDTs nor for molecular POCTs. However, the potential of simple, affordable tests, such as Ag-RDTs, is limited by poor sensitivity while the use of highly sensitive POC molecular platforms remains limited by their cost. To date, the lack of accurate, affordable POC MPXV-specific assays with potential to differentiate clades, limits diagnostic capacities as well as our understanding of the virus and its epidemiology. Funding: This work was supported by FIND and internal funds of the Centre for Emerging Viral Diseases. Mpox diagnostic tests were provided by FIND and the World Health Organization (WHO). MOD was supported by Schmidt Science Fellows, in partnership with the Rhodes Trust.


  • Open Access

    Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors

    by Hiba Mechahougui, Léna Royston, Catia Vieira Gomes, Laurent Kaiser, Thibaud Koessler, Timothée Olivier, Nicolas Mach, S. Intidhar Labidi-Galy, Kaushal Parikh, Alfredo Addeo

    Viral infections are estimated to contribute to 12% to 20% of all cancers worldwide, with virus-driven malignancies disproportionately affecting low- and middle-income countries, whereas metabolic and nonviral factors predominate in high-income regions. Key oncogenic viruses that cause solid tumors include high-risk human papillomaviruses, Epstein–Barr virus, hepatitis B virus, hepatitis C virus, Kaposi sarcoma–associated herpesvirus, and Merkel cell polyomavirus. Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by boosting immune responses against tumors. Although viral infection–associated tumors often exhibit “hot” immune profiles, clinical outcomes with ICIs remain inconsistent. Some studies report improved survival in virus-associated cancers, whereas others indicate no clear benefit, which might reflect high variability in tumor microenvironments and immune responses. In this review, we aim to explore the direct and indirect contribution of different viruses to carcinogenesis in solid tumors, with a particular focus on immunotherapy effectiveness based on infection status.


  • Open Access

    Routine Immunisation Coverage Shows Signs of Recovery at Global Level Postpandemic, but Important Declines Persist in About 20% of Countries

    by Beth Evans, Laurent Kaiser, Olivia Keiser, Thibaut Jombart

    Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the cessation of most nonpharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to the level of prepandemic trends and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared with expectations (based on time-series forecasting). Methods: We quantified global and country-level routine immunisation diphtheria–tetanus–pertussis (DTP) coverage trends postpandemic (2023) compared with prepandemic trends using time-series forecasting across 190 countries. We used discriminant analysis of principal components and random forests to identify relevant predictors of country-level coverage performance, including twenty-eight indicators of health system strength, health workforce, country income, pandemic containment, economic and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1–4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translated to the total number of immunised children almost reverting to expected levels because of decreasing fertility reducing global-level immunisation target populations. At the country level, notable disruption remained in over thirty countries (16.8% of countries below expectations, 81.6% within expected ranges, and 1.6% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in about 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.


  • Open Access

    Routine Immunisation Coverage Shows Signs of Recovery at Global-Level Post Pandemic, But Important and Declines Persist in 20% of Countries

    by Beth Evans, Laurent Kaiser, Olivia Keiser, Thibaut Jombart

    Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the end of most non-pharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to pre-pandemic trends, and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared to expectations (based on time-series forecasting). Methods: We quantify global and country-level routine immunisation diphtheria-tetanus-pertussis (DTP) coverage trends post-pandemic (2023) compared to pre-pandemic trends using time-series forecasting across 190 countries. We used Discriminant Analysis of Principal Components and Random Forests to identify relevant predictors of country-level coverage performance, including 28 indicators of health system strength, health workforce, country income, pandemic containment, economic, and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1% - 4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translates to the total number of immunised children almost reverting to expected levels, owing to decreasing fertility reducing global-level immunisation target populations. At a country-level, notable disruption remaining in over 30 countries (17.6% of countries below expectations, 81.6 within expected ranges, and 1.7% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.


  • Open Access

    SCANellome V2: Update of the Primate Anellovirus Reference Sequences Database

    by Florian Laubscher, Laurent Kaiser, Samuel Cordey

    Anelloviruses are ubiquitous in humans and represent a major component of the human virome. Its best-known representative is Torque teno virus (i.e., the Alphatorquevirus genus), which is considered a potential immunity biomarker. Recent metagenomic investigations revealed not only the extraordinary genomic diversity of anellovirus sequences, but also that co-detection of genera, genotypes, or species seems to be the rule in humans. SCANellome was developed to represent a user-friendly tool to analyze the primate (both human and non-human) anellovirus composition at the genus, species, and genotype level from metagenomics data based on an up-to-date database. This SCANellome update includes >900 additional reference sequences from GenBank. Using a clustering at 90% identity, the FASTA database was updated and generated 134 new representative sequences. Based on ORF1, the analysis of these new sequences indicates the presence of 206 potential new species, including four nonhuman primates, and adds four new non-human primate species which will be the subject of a proposal to the International Committee on Taxonomy of Viruses (ICTV). In addition, SCANellome V2 provides now the user with an interactive up-to-date phylogenetic analysis (of ORF1) to show the distribution among the 12 human and nonhuman primate genera of these new potential species. Finally, the Anelloviridae taxonomy was updated to rename species names in binomial format as required by the ICTV.


  • Open Access

    Immune escape and replicative capacity of Omicron lineages BA.1, BA.2, BA.5.1, BQ.1, XBB.1.5, EG.5.1 and JN.1.1

    by Meriem Bekliz, Manel Essaidi-Laziosi, Kenneth Adea, Krisztina Hosszu-Fellous, Catia Alvarez, Mathilde Bellon, Pascale Sattonnet-Roche, Olha Puhach, Damien Dbeissi, Maria Eugenia Zaballa, et al.

    In the 5th year after the emergence of SARS-CoV-2, Omicron lineages continue to evolve and cause infections. Here, we used eight authentic SARS-CoV-2 isolates to assess their capacity to escape immunity of different exposure histories and their replicative capacity in polarized human airway epithelial cells (HAE) derived from the nasal and bronchial epithelium. Using live-virus neutralization assays of 108 human sera or plasma of different immunological backgrounds, progressive immune escape was observed from B.1 (ancestral virus) to EG.5.1, but no significant difference between EG.5.1 and JN.1.1. Vaccinated individuals without natural infection and individuals with a single infection, but no vaccination showed markedly reduced or completely lost neutralization against the latest variants, while in those with hybrid immunity almost all sera showed some neutralization capacity. Furthermore, although absolute titers differed between groups, the pattern of immune escape between the variants remains comparable with strongest loss of neutralization observed for the latest variants. In vitro studies with HAE at 33 degree C and 37 degree C showed some, but minor differences in virus replication and innate immune responses upon infection. Notably, infection with XBB.1.5, EG.5.1 and JN.1.1 showed slightly increased viral growth in nasal HAE at 33 degree C. Altogether, these data underscore increasing immune escape across heterogeneous immunological backgrounds with gradually increasing antibody escape of evolving Omicron lineages until variant EG.5.1, but not any further for the latest dominant lineage JN.1.1. They also suggest that viral dynamics within Omicron lineages are driven by a combination of immune evasion and increase in viral replication.


  • Open Access

    S-Gene Target Failure as an Effective Tool for Tracking the Emergence of Dominant SARS-CoV-2 Variants in Switzerland and Liechtenstein, Including Alpha, Delta, and Omicron BA.1, BA.2, and BA.4/BA.5

    by Dominique Hilti, Faina Wehrli, Sabine Berchtold, Susanna Bigler, Thomas Bodmer, Helena M. B. Seth-Smith, Tim Roloff, Philipp Kohler, Christian R. Kahlert, Laurent Kaiser, et al.

    During the SARS-CoV-2 pandemic, the Dr. Risch medical group employed the multiplex TaqPathTM COVID-19 CE-IVD RT-PCR Kit for large-scale routine diagnostic testing in Switzerland and the principality of Liechtenstein. The TaqPath Kit is a widely used multiplex assay targeting three genes (i.e., ORF1AB, N, S). With emergence of the B.1.1.7 (Alpha) variant, a diagnostic flaw became apparent as the amplification of the S-gene target was absent in these samples due to a deletion (ΔH69/V70) in the Alpha variant genome. This S-gene target failure (SGTF) was the earliest indication of a new variant emerging and was also observed in subsequent variants such as Omicron BA.1 and BA4/BA.5. The Delta variant and Omicron BA.2 did not present with SGTF. From September 2020 to November 2022, we investigated the applicability of the SGTF as a surrogate marker for emerging variants such as B.1.1.7, B.1.617.2 (Delta), and Omicron BA.1, BA.2, and BA.4/BA.5 in samples with cycle threshold (Ct) values < 30. Next to true SGTF-positive and SGTF-negative samples, there were also samples presenting with delayed-type S-gene amplification (higher Ct value for S-gene than ORF1ab gene). Among these, a difference of 3.8 Ct values between the S- and ORF1ab genes was found to best distinguish between “true” SGTF and the cycle threshold variability of the assay. Samples above the cutoff were subsequently termed partial SGTF (pSGTF). Variant confirmation was performed by whole-genome sequencing (Oxford Nanopore Technology, Oxford, UK) or mutation-specific PCR (TIB MOLBIOL). In total, 17,724 (7.4%) samples among 240,896 positives were variant-confirmed, resulting in an overall sensitivity and specificity of 93.2% [92.7%, 93.7%] and 99.3% [99.2%, 99.5%], respectively. Sensitivity was increased to 98.2% [97.9% to 98.4%] and specificity lowered to 98.9% [98.6% to 99.1%] when samples with pSGTF were included. Furthermore, weekly logistic growth rates (α) and sigmoid’s midpoint (t0) were calculated based on SGTF data and did not significantly differ from calculations based on comprehensive data from GISAID. The SGTF therefore allowed for a valid real-time estimate for the introduction of all dominant variants in Switzerland and Liechtenstein.


  • Open Access

    Direct Dengue Virus Genome Sequencing from Antigen NS1 Rapid Diagnostic Tests: A Proof-of-Concept with the Standard Q Dengue Duo Assay

    by Francisco-Javier Pérez-Rodríguez, Florian Laubscher, Valentin Chudzinski, Laurent Kaiser, Samuel Cordey

    With nearly half of the world’s population being at risk of infection, dengue virus represents a major global health issue. The use of dengue antigen rapid diagnostic tests (Ag-RDTs) represents an alternative to PCR methods for the diagnosis of acute infections since they display excellent sensitivities and specificities and can be performed outside the laboratory. The high genetic diversity of the dengue virus genome represents a challenge for vaccine development, and the progressive expansion of this virus into previously nonendemic regions justifies the implementation of a genomic surveillance program. In this proof-of-concept study, we show the feasibility of sequencing dengue virus genomes directly from positive Ag-RDT (Standard Q Dengue Duo Test assay, n = 7) cassettes stored up to 31 days at room temperature after testing. For 5 of the 7 samples, a high number of reads were obtained allowing phylogenetic analyses to be carried out to determine not only the serotypes (dengue 1, 2, 3 and 4 were detected) but also the genotypes. Furthermore, in one sample, our unbiased metagenomic next-generation sequencing approach made it possible to detect epizootic hemorrhagic disease virus sequences, an arthropod-transmitted virus in ruminants. To conclude, as such an approach requires no cold storage or freezing of samples, dengue Ag-RDTs represent a very pragmatic and robust alternative for the genomic surveillance of dengue virus.